-
公开(公告)号:AT139526T
公开(公告)日:1996-07-15
申请号:AT93101842
申请日:1993-02-05
Applicant: HOECHST AG
Inventor: LANG HANS-JOCHEN DR , MANIA DIETER DR , WEICHERT ANDREAS DR , SCHOLZ WOLFGANG DR , ALBUS UDO DR , ENGLERT HEINRICH DR , LANG FLORIAN PROF DR
IPC: A61K31/155 , A61K31/18 , A61K31/275 , A61P1/16 , A61P3/08 , A61P3/10 , A61P9/00 , A61P9/04 , A61P9/06 , A61P9/08 , A61P9/10 , A61P9/12 , A61P13/02 , A61P15/00 , A61P35/00 , A61P35/04 , C07C217/44 , C07C311/16 , C07C311/37 , C07C311/39 , C07C311/47 , C07C317/42 , C07C317/44 , C07C323/65
Abstract: There are described benzoylguanidines of the formula I where R(1) is equal to R(4)-SOm or R(5)R(6)N-SO2-, where R(4) and R(5) are equal to alk(en)yl, -CnH2n-R(7), and where R(7) is equal to cycloalkyl or phenyl, where R(5) also denotes H, R(6) is equal to H or C1-C4-alkyl, R(2) is hydrogen, halogen, alkyl, -O-(CH2)mCpF2p+1, -X-R(10), where X is equal to O, S, NR(11), R(10) is equal to H, (cyclo)alkyl(methyl), -CnH2n-R(12) where R(12) is equal to phenyl, R(3), inter alia, is defined as R(1), and their pharmaceutically tolerable salts. The compounds I are prepared by reaction of compounds of the formula II in which L represents a leaving group which can be easily substituted nucleophilically, with guanidine. Compounds I are outstandingly suitable as antiarrhythmic medicaments having a cardioprotective component for infarct prophylaxis and infract treatment and for the treatment of angina pectoris, where they also preventively inhibit or strongly decrease the pathophysiological processes during the formation of ischaemically induced damage. They are moreover distinguished by a strong inhibitory action on cell proliferation. They can therefore be used as antiatherosclerotics, agents against diabetic late complications, cancers, fibrotic disorders such as pulmonary fibrosis, fibrosis of the liver or fibrosis of the kidneys. They are effective inhibitors of the cellular sodium/protons antiporter (Na /H exchanger).
-
公开(公告)号:CZ9204033A3
公开(公告)日:1993-12-15
申请号:CS403392
申请日:1992-12-31
Applicant: HOECHST AG
Inventor: ENGLERT HEINRICH DR , MANIA DIETER DR , LANG HANS-JOCHEN DR , SCHOLZ WOLFGANG DR , LINZ WOLFGANG DR , ALBUS UDO DR
IPC: A61K31/155 , A61K31/165 , A61K31/445 , A61P1/16 , A61P3/08 , A61P3/10 , A61P9/00 , A61P9/04 , A61P9/06 , A61P9/08 , A61P9/10 , A61P9/12 , A61P13/02 , A61P15/00 , A61P35/00 , C07C279/22 , C07D213/65 , C07D295/14 , C07D295/155 , C07C279/20 , A61K31/40 , C07C277/08
CPC classification number: C07D295/155 , C07C279/22 , C07D213/65
-
公开(公告)号:CZ403592A3
公开(公告)日:1993-12-15
申请号:CS403592
申请日:1992-12-31
Applicant: HOECHST AG
Inventor: ENGLERT HEINRICH DR , MANIA DIETER DR , WETTLAUFER DAVID DR , KLAUS ERIK DR
IPC: A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4425 , A61P9/00 , A61P21/00 , C07D213/64 , C07D213/79 , C07D213/80 , C07D213/81 , C07D213/89 , C07D401/12
Abstract: Arylcarbonylaminoalkyl-dihydro-oxo-pyridines of Formula I are disclosed wherein aryl is an aromatic or heteroaromatic system, n is zero through 5; R and R(1), are hydrogen, or loweralkyl; W is hydrogen, (hetero)-(aryl)-loweralkyl; Z is hydrogen, CH2OR(2), CHO, (CO)OR(2), (CO)NR(2)2. Processes for the preparation of compound I are also disclosed. Compounds I are suitable for the treatment of disorders of the cardiovascular system, for example of hypertension, of cardiac insufficiency or of disturbances of blood flow in the coronary systems such as, for example, angina. Disturbances of cerebral and peripheral blood flow are likewise influenced beneficially. Furthermore, compounds I are able to influence smooth-muscle organs such as uterus, bronchi, intestines and biliary system, the urinary tract (ureter, bladder and urethra) in the sense of spasmolysis. They are therefore also suitable for the treatment of diseases associated with spasms of these organs, for example for the treatment of premature labor in pregnancy, of ureteral or biliary colic, of obstructive airway diseases such as asthma, of disturbances of intestinal motility such as, for example, of irritable colon or of bladder incontinence. Additionally, compounds of formula I can serve as anti-convulsants in the treatment of epilepsy and as hair growth inducers in the treatment of baldness.
-
公开(公告)号:BR9200011A
公开(公告)日:1992-09-08
申请号:BR9200011
申请日:1992-01-03
Applicant: HOECHST AG
Inventor: WAGNER ADALBERT DR , ENGLERT HEINRICH DR , KLEEMANN HEINZ-WERNER DR , GERHARDS HERMANN DR , SCHOELKENS BERNWARD DR , BECKER REINHARD DR , LINZ WOLFGANG DR
IPC: A61K31/40 , A61K31/415 , A61K31/425 , A61K31/435 , A61K31/44 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/445 , A61K31/505 , A61K31/535 , A61K31/54 , A61K31/64 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P13/02 , A61P15/00 , A61P43/00 , C07D207/34 , C07D207/36 , C07D233/54 , C07D233/66 , C07D233/68 , C07D233/70 , C07D233/84 , C07D233/90 , C07D249/02 , C07D255/02 , C07D257/02 , C07D257/04 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D453/02 , C07D521/00 , C07D231/12 , C07D409/14
Abstract: Azole derivative of the general formula (I) in which A, L, O, R , X, Y, Z and q have the meanings given, a process for their preparation, pharmaceutical preparations and the use of the compounds are described. Azole derivatives of the formula I where the symbols have, for example, the following meanings: R = (C2-C10)-alkyl Z = nitrogen X and Y = independently of one another CR L = -CH2- q = zero or 1 A = biphenyl radical which is substituted, for example, by R R = halogen or hydrogen R = SO2-NH-CO-OR and R = phenyl, are highly active antagonists of angiotensin II receptors.
-
公开(公告)号:DE3831697A1
公开(公告)日:1990-03-22
申请号:DE3831697
申请日:1988-09-17
Applicant: HOECHST AG
Inventor: UTZ ROLAND DR , ENGLERT HEINRICH DR , SCHOELKENS BERNWARD DR , KLAUS ERIK DR
IPC: C07D313/08 , A61K31/40 , A61K31/44 , A61K31/443 , A61K31/55 , A61P1/16 , A61P9/00 , A61P11/00 , A61P13/02 , A61P15/00 , C07D405/04 , C07D493/04
Abstract: 2,3,4,5-Tetrahydro-1-benzoxepines of the formula I with R , inter alia, equal to H, alkyl, alkoxy, hal, alkylsulphonyl, arylsulphonyl, R equal to H, alkyl, alkoxy, OH, R to R , H or alkyl and X equal to have outstanding activity as antihypertensives, as coronary therapeutics, as agents for the treatment of heart failure, of disturbances of cerebral and peripheral blood flow or of intestinal motility disorders, premature labour, obstructions of the airways or of the urinary tract or of the biliary tract or as spasmolytics.
-
公开(公告)号:DE3208190A1
公开(公告)日:1983-09-08
申请号:DE3208190
申请日:1982-03-06
Applicant: HOECHST AG
Inventor: ENGLERT HEINRICH DR , LANG HANS-JOCHEN DR , HROPOT MAX DR , KAISER JOACHIM DR
IPC: A61K31/135 , A61K31/40 , A61K31/535 , A61K31/54 , A61P3/00 , A61P7/10 , A61P9/12 , C07C43/21 , C07C67/00 , C07C313/00 , C07C315/04 , C07C317/00 , C07C317/22 , C07C317/32 , C07C317/36 , C07D277/04 , C07D295/08 , C07D295/096 , C07D307/52 , C07C147/12 , C07C147/14 , C07C147/10
Abstract: 1. Claims for the Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE 2-Aminomethylphenols of the formula I see diagramm : EP0088346,P33,F2 in which R represents hydrogen or alkyl having 1 or 2 C atoms, R**1 represents alkyl having 1 to 8 C atoms, cycloalkyl having 3 to 12 C atoms and up to 8 ring members, alkenyl having 2 to 8 C atoms or cycloalkenyl having 5 to 12 C atoms and up to 8 ring members, it being possible for each of the aforementioned radicals to be substituted with 1 to 5 identical or different halogen atoms, R**2 and R**4 are identical or different and denote hydrogen, halogen, alkyl having 1 or 2 C atoms or alkoxy having 1 or 2 C atoms, R**3 denotes halogen, alkyl having 1 to 12 C atoms or cycloalkyl having 3 to 12 C atoms and up to 8 ring members, R**5 and R**6 are identical or different and represent hydrogen, alkyl having 1 to 6 C atoms, cycloalkyl having 3 to 10 C atoms and up to 8 ring members or the radical -[CH2 ]o -Ar, wherein o = 1 or 2, the -[CH2 ]o - chain can be substituted by 1 or 2 (C1 or C2 )-alkyl groups and Ar is a 5- or 6- membered aromatic or heteroaromatic system, which is optionally substituted by 1 to 3 identical or different radicals (C1 or C2 )-alkyl, (C1 or C2 )-alkoxy or halogen, and n is 1 or 2, it being possible for the radicals R**5 and R**6 and/or two of the radicals R**2 , R**3 and R**4 also to form a -[CH2 ]m - chain having m = 3 to 6, which can optionally be substituted by 1 or 2 methyl groups and, in the case of R**5 and R**6 , can also be interrupted by 1 or 2 oxygen atoms, sulfur atoms and/or imino groups, and their physiologically tolerated salts. 1. Claims for the Contracting State : AT A process for the preparation of the 2-aminomethylphenols of the formula I see diagramm : EP0088346,P35,F4 in which R represents hydrogen or alkyl having 1 or 2 C atoms, R**1 represents alkyl having 1 to 8 C atoms, cycloalkyl having 3 to 12 C atoms and up to 8 ring members, alkenyl having 2 to 8 C atoms or cycloalkenyl having 5 to 12 C atoms and up to 8 ring members, it being possible for each of the aforementioned radicals to be substituted with 1 to 5 identical or different halogen atoms, R**2 and R**4 are identical or different and denote hydrogen, halogen, alkyl having 1 or 2 C atoms or alkoxy having 1 or 2 C atoms, R**3 denotes halogen, alkyl having 1 to 12 C atoms or cycloalkyl having 3 to 12 C atoms and up to 8 ring members, R**5 and R**6 are identical or different and represent hydrogen, alkyl having 1 to 6 C atoms, cycloalkyl having 3 to 10 C atoms and up to 8 ring members or the radical -[CH2 ]o -Ar, wherein o = 1 or 2, the -[CH2 ]o - chain can be substituted by 1 or 2 (C1 or C2 )-alkyl groups and Ar is a 5- or 6-membered aromatic or heteroaromatic system, which is optionally substituted by 1 to 3 identical or different radicals (C1 or C2 )-alkyl, (C1 or C2 )-alkoxy or halogen, and n is 1 or 2, it being possible for the radicals R**5 and R**6 and/or two of the radicals R**2 , R**3 and R**4 also to form a -[CH2 ]m - chain having m = 3 to 6, which can optionally be substituted by 1 or 2 methyl groups and, in the case of R**5 and R**6 , can also be interrupted by 1 or 2 oxygen atoms, sulfur atoms and/or imino groups, and their physiologically tolerated salts, which comprises a) reacting a compound of the formula II see diagramm : EP0088346,P36,F1 wherein n, R**1 , R**2 , R**3 and R**4 have the abovementioned meanings, with an N-hydroxymethylcarboxamide of the general formula III see diagramm : EP0088346,P36,F2 in which R has the abovementioned meaning, R**5 denotes hydrogen or alkyl having 1 to 4 C atoms and R**7 represents hydrogen, optionally halogen-substituted alkyl having 1 to 4 C atoms or aryl having 6 to 10 C atoms, or in which R**5 and the radical COR**7 together represent the o-phthaloyl radical, to give a compound of the general formula IV see diagramm : EP0088346,P36,F3 and removing the acyl radical R**7 -CO by hydrolysis, b) reacting a compound of the formula II, in which the radicals R**1 to R**4 and n have the abovementioned meanings, in the presence of formaldehyde, with an amine of the general formula V see diagramm : EP0088346,P36,F4 in which R**5 and R**6 have the meanings mentioned in claim 1 with the exception of hydrogen, c) reacting a compound of the general formula VI see diagramm : EP0088346,P36,F5 in which n and R to R**4 have the abovementioned meanings and Z represents a leaving group, with an amine of the general formula H-N = Y, wherein Y represents an amine-protective group or the radicals R**5 and R**6 defined in claim 1, it being possible for R**6 also to be an amine-protective group, to give a compound of the general formula VII see diagramm : EP0088346,P37,F1 and, if appropriate, removing the amine-protective group by hydrolysis or hydrogenolysis, or d) reacting compounds of the general formula XIV see diagramm : EP0088346,P37,F2 in which n and R to R**4 have the abovementioned meanings, with an amine of the formula R**5 -NH2 , with R**5 having the abovementioned meaning, to give Schiff's bases of the formula XV see diagramm : EP0088346,P37,F3 in which n and R to R**5 have the abovementioned meanings, and reducing the latter to give a compound of the formula I, and optionally converting the compound of the formula I obtained according to one of the variants a) - d) into its physiologically tolerated salts.
-
公开(公告)号:HU227308B1
公开(公告)日:2011-03-28
申请号:HU9503931
申请日:1995-12-29
Applicant: HOECHST AG
Inventor: KAISER JOACHIM DR , ENGLERT HEINRICH DR , GOEGELEIN HEINZ DR , MANRIA DIETER DR , GERLACH UWE DR
IPC: C07C311/51 , C07D331/02 , A61K31/18 , A61K31/38 , A61K31/64 , A61P9/00 , A61P9/02 , A61P9/06 , A61P9/10 , C07C233/00 , C07C303/40 , C07C311/58 , C07C327/46 , C07C335/42 , C07D203/08 , C07D295/00 , C07D303/48
Abstract: N-(3-substd. benzensulphonyl)-urea or -thiourea derivs. of formula (I) and their salts are new. R1 = H, 1-7C alkyl or 3-7C cycloalkyl; R2 = H, F, Cl, 1-6C alkyl, 1-6C alkoxy, 1-6C mercaptoalkyl, 3-6C cycloalkyl or CbH2b+1, in which one or more C can be replaced by Het; Het = heteroatoms, e.g. O, NH or S; b = 1-8; 1-8C alkyl in which 1-4C may be replaced by O, N or S; R3 = H, 1-12C alkyl, 3-10C cycloalkyl, 1-6C fluoroalkyl, 3-6C fluorocycloalkyl or CaH2a+1 in which 1-4C are replaced by Het; a = 1-10; R4 = aryl or as R3; or R3+R4 = CbH2b, in which one or more CH2 can be replaced by Het; R5 = as R4; R6 = as R4 but not 3-10C cycloalkyl; Q, X = O or S; Y = -(C(R7)2)c, O, S or NH; c = 1-4; R7 = H, 1-4C alkyl, F, Cl or Br.
-
公开(公告)号:HU226463B1
公开(公告)日:2008-12-29
申请号:HU9503879
申请日:1995-12-28
Applicant: HOECHST AG
Inventor: KAISER JOACHIM DR , ENGLERT HEINRICH DR , GOEGELEIN HEINZ DR , MANRIA DIETER DR , GERLACH UWE DR
IPC: A61K31/18 , C07C311/51 , A61K31/64 , A61P9/00 , A61P9/04 , A61P9/06 , A61P9/10 , C07C233/00 , C07C303/40 , C07C311/58 , C07C311/59 , C07C327/40 , C07C335/42
Abstract: Substd. benzene sulphonyl urea and thiourea derivs. of formula (I) and their salts are new. R1 = H, Me or CF3; R2 = 4-10C alkoxy with 1-6C replaced by O, S or NH; Q = O or S; Y = ÄC(R3)2Üm; R3 = H, Me or Et; R' = H, halo or 1-6C alkyl; R" = halo, 1-4C alkoxy or 1-4C alkyl; and m = 1-4.
-
公开(公告)号:CZ290738B6
公开(公告)日:2002-10-16
申请号:CZ28096
申请日:1996-01-30
Applicant: HOECHST AG
Inventor: ENGLERT HEINRICH DR , HARTUNG JENS DR , CRAUSE PETER DR , MANIA DIETER DR , GOGELEIN HEINZ DR , KAISER JOACHIM DR
IPC: A61K31/38 , A61K31/381 , A61K31/64 , A61P9/00 , A61P9/04 , A61P9/06 , A61P9/10 , A61P43/00 , C07C335/00 , C07D333/34
Abstract: In the present invention, there are described substituted thiophenesulfonyl ureas and thioureas of the general formula I, in which R(1) represents hydrogen, halogen or an alkyl group containing 1 to 2 carbon atoms, R(2) represents hydrogen or methyl, X represents oxygen or sulfur and Y and Z that are the same or different represent each hydrogen, fluorine, chlorine, bromine, iodine an alkyl group containing 1 to 2 carbon atoms or an alkoxyl group having 1 to 2 carbon atoms, and their physiologically acceptable salts. These compounds exhibit activity on cardiovascular system. Disclosed is also a process for preparing these compounds as well as a medicament in which they are comprised.
-
公开(公告)号:GR3035537T3
公开(公告)日:2001-06-29
申请号:GR20010400378
申请日:2001-03-09
Applicant: HOECHST AG
Inventor: LAL BANSI DR , GIDWANI RAMESH MATIORAM DR , RAJAGOPALAN RAMANUJAM , PANICKER RADHA , SANKAR CHINNAKULANDAI , LANG HANS-JOCHEN DR , ENGLERT HEINRICH DR , SCHOLZ WOLFGANG DR
IPC: A61K31/472 , A61P9/00 , A61K31/47 , A61P9/04 , A61P9/06 , A61P9/10 , C07D217/26 , C07D401/04 , C07D401/12 , C07D413/04 , C07D413/12
Abstract: Described are guanidinocarbonyl isoquinolines I, with R(1) hydrogen, (amino)(cyclo)(aryl)alk(en)yl, (heteroaryl); R(2) hydrogen, halogen, alkyl, or Aryl; G X(2), X(3) and X(4) hydrogen, halogen, nitro, amino, alkyl, sulfonamide, (mono)(di)(lower alkyl)(amino), benzyloxy, hydroxy; X(1) hydrogen, oxygen, sulfur and NR(7)R(8), and their pharmaceutically acceptable salts; described is also the process for their prepara-tion, their use as medicaments, and medicaments containing them for treating congestive heart failure, arrhythmic conditions as well as cardioprotective agents in mammals.
-
-
-
-
-
-
-
-
-